Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 4/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL26949 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4094346 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21372603 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27925300 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL25331832 | 0.92 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10561739 | 0.92 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL29188646 | 0.92 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL2701972 | 0.92 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL29089410 | 0.92 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8647305 | 0.92 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190327961-A1 | STABLE SOLID COMPOSITION BASED ON AN AROMATIC COMPOUND AND USES THEREOF | REMMAL, ADNANE (MA) | 2019-10-31 | — | — | US | claimed |
| EP-3541182-A1 | STABLE SOLID COMPOSITION BASED ON AN AROMATIC COMPOUND AND USES THEREOF | Remmal, Adnane (MA) | 2019-09-25 | — | — | EP | claimed |
| US-20190327961-A1 | STABLE SOLID COMPOSITION BASED ON AN AROMATIC COMPOUND AND USES THEREOF | REMMAL, ADNANE (MA) | 2019-10-31 | — | — | US | disclosed |
| EP-3541182-A1 | STABLE SOLID COMPOSITION BASED ON AN AROMATIC COMPOUND AND USES THEREOF | Remmal, Adnane (MA) | 2019-09-25 | — | — | EP | disclosed |
| WO-2016022973-A1 | INSUFFLATION APPARATUS AND METHOD OF USE | ENDOINSIGHT, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20140081169-A1 | SYSTEM AND METHOD OF TETHERLESS INSUFFLATION IN COLON CAPSULE ENDOSCOPY | VANDERBILT UNIVERSITY (US) | 2014-03-20 | — | — | US | disclosed |
| US-7846424-B2 | Non-pressurized post-application expanding composition | AVON PRODUCTS, INC (US) | 2010-12-07 | — | — | US | disclosed |
| CN-100556395-C | Non-pressurized post-application expanding compositions | AVON PROD INC (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-1575536-A4 | TOPICAL USE OF POST-APPLICATION EXPANDING COSMETIC COMPOSITION | AVON PROD INC (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1575546-A4 | NON-PRESSURIZED POST-APPLICATION EXPANDING COMPOSITION | AVON PROD INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20060147399-A1 | Non-pressurized post-application expanding composition | CITIBANK, N.A., LONDON BRANCH | 2006-07-06 | — | — | US | disclosed |
| US-20060088486-A1 | Topical use of post-application expanding cosmetic composition | AVON PRODUCTS, INC. | 2006-04-27 | — | — | US | disclosed |
| CN-1703196-A | Non-pressurized post-application expanding compositions | AVON PROD INC (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1575546-A2 | NON-PRESSURIZED POST-APPLICATION EXPANDING COMPOSITION | Avon Products, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575536-A1 | TOPICAL USE OF POST-APPLICATION EXPANDING COSMETIC COMPOSITION | Avon Products, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004060332-A1 | TOPICAL USE OF POST-APPLICATION EXPANDING COSMETIC COMPOSITION | AVON PRODUCTS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060292-A2 | NON-PRESSURIZED POST-APPLICATION EXPANDING COMPOSITION | AVON PRODUCTS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0494972-A4 | EFFERVESCENT DOSAGE FORM AND METHOD OF ADMINISTERING SAME | — | 1992-08-12 | — | — | EP | disclosed |
| EP-0494972-A1 | EFFERVESCENT DOSAGE FORM AND METHOD OF ADMINISTERING SAME. | CIMA LABS INC (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991004757-A1 | EFFERVESCENT DOSAGE FORM AND METHOD OF ADMINISTERING SAME | CIMA LABS, INC. (US) | 1991-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088486-A1 | Topical use of post-application expanding cosmetic composition | CUTA, PLIN5, MITF | MEN1 2878/4885ALDH1A1 2937/4885HMGCR 1049/4885 |
| US-20060147399-A1 | Non-pressurized post-application expanding composition | NONO, SMURF1, SMURF2 | MEN1 2788/4885ALDH1A1 3833/4885HMGCR 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.